

EMPACTA – Salama, C; et al. *NEJM* 2021 (Published: Dec 17, 2020)

Study Design	Multicenter, double-blind, placebo, RCT – Severe COVID-19 – (2:1)	
Location	Global – 39 hospitals / High risk and minority populations	
Inclusion	Severe COVID-19 pneumonia + SpO ₂ < 94% (not on MV)	
Exclusion	CPAP/BIPAP/MV	
Intervention	Tocilizumab 8 mg/kg IV (up to 800 mg)	
Control	Placebo	
	Tocilizumab n=249	Control n=128
Primary Outcomes		
Death or MV at day 28	12%***	19%
MV at day 28	8%	13%
Time to hospital discharge, days	6	8
Time to clinical improvement, days	6	7
Death at day 28	10%	9%
Comments: *** p<0.05 compared to control group No biomarker driven decision Corticosteroids within 7 days prior to first dose was 80% in the toci arm and 87.5% in the control arm.		
Abbreviations: BIPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; HFO, high-flow oxygen; MV, mechanical ventilation; O ₂ , oxygen; RCT, randomized controlled trial		